In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment ...
Monte Rosa’s MRT-8102 Phase 1 shows deep NEK7 degradation and strong hsCRP drops; plus $200M raise extends runway. Learn more ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback